344 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast PeerView

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Nicole Lamanna, MD - Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations

    Nicole Lamanna, MD - Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.

    Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent educational grant from AstraZeneca.

    Disclosure information is available at the beginning of the video presentation.

    • 28 min
    Sumanta Kumar Pal, MD, FASCO - A Roadmap for Modern RCC Care: Navigating Personalized Treatment Selection and Sequencing

    Sumanta Kumar Pal, MD, FASCO - A Roadmap for Modern RCC Care: Navigating Personalized Treatment Selection and Sequencing

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GXM865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.

    A Roadmap for Modern RCC Care: Navigating Personalized Treatment Selection and Sequencing

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Kidney Cancer Research Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This educational activity is supported through medical education grants from AVEO Pharmaceuticals, Inc., Bristol Myers Squibb, and Exelixis, Inc.

    Disclosure information is available at the beginning of the video presentation.

    • 1 hr 27 min
    Karim Fizazi, MD, PhD - Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

    Karim Fizazi, MD, PhD - Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWU865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

    Unlocking the Power of Modern Therapeutic Regimens for Prostate Cancer: Experts Put the Pressure on Key Evidence and Real-World Strategies to Optimize Patient Care

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity has been supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Novartis Pharmaceuticals Corporation.

    Disclosure information is available at the beginning of the video presentation.

    • 1 hr 17 min
    Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

    Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/VTE865. CME/MOC/NCPD/AAPA credit will be available until July 2, 2025.

    Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported through educational grants from Astellas, BeiGene, and Bristol Myers Squibb.

    Disclosure information is available at the beginning of the video presentation.

    • 1 hr 35 min
    Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

    Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

    Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Cholangiocarcinoma Foundation, and the Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

    Disclosure information is available at the beginning of the video presentation.

    • 1 hr 22 min
    Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

    Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/WUM865. CME/MOC/CPD/NCPD/CPE/AAPA credit will be available until June 21, 2025.

    Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an educational grant from Lilly.

    Disclosure information is available at the beginning of the video presentation.

    • 56 min

Top Podcasts In Science

You Might Also Like

ASCO Daily News
American Society of Clinical Oncology (ASCO)
Two Onc Docs
Sam and Karine
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
PVI, PeerView Institute for Medical Education
Plenary Session
Vinay Prasad, MD MPH
NEJM This Week
NEJM Group
NEJM Interviews
NEJM Group